HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High prevalence of late adverse events in malignant bone tumour survivors diagnosed at adult age.

AbstractBACKGROUND:
Late treatment-related adverse events are particularly prevalent in survivors of childhood bone cancer because of the combination of cytotoxic drugs, major surgery and radiotherapy. Existing studies for late toxicity in survivors of Ewing's sarcoma (ES) and osteosarcoma (OS) diagnosed at adult age have focused on specific sequelae. We investigated a broad spectrum of potential late effects in these patients.
METHODS:
Relapse-free OS and ES patients aged ≥ 16 at diagnosis and treated at the Radboud University Medical Centre (1982-2007) were invited for systematic late toxicity screening. This included history taking, physical examination, echocardiogram, bone densitometry, audiogram, and serum and urine screening for renal toxicity and infertility. Adverse events were graded according to the Common Terminology Criteria for Adverse Events version 3.0.
RESULTS:
In 24 survivors (63% male, mean age at screening 45.7 years, mean follow-up 10.9 years, 70% OS) we found a median of eight adverse events. Frequent findings included abnormal gait, osteoporosis, pain, left ventricular systolic dysfunction, obesity and nephropathy. The maximum grade of any adverse event was mild in four (17%), moderate in 11 (46%), severe in six (25%), and disabling in three cases (13%). There was a trend towards more events in patients diagnosed at an older age.
CONCLUSION:
The incidence of late adverse events in this study of survivors of bone tumours diagnosed at adult age is higher than in any previously published childhood cancer survivorship study. Older patients seem to be particularly at risk. Our findings underscore the need for systematic screening of late effects in bone cancer survivors of adult age at diagnosis.
AuthorsA C M van de Luijtgaarden, L Kapusta, L Bellersen, J P M Bokkerink, S E J Kaal, Y M H Versleijen-Jonkers, H W B Schreuder, W T A van der Graaf
JournalThe Netherlands journal of medicine (Neth J Med) Vol. 72 Issue 10 Pg. 516-22 (Dec 2014) ISSN: 1872-9061 [Electronic] Netherlands
PMID26219756 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Doxorubicin
Topics
  • Academic Medical Centers
  • Adolescent
  • Adult
  • Antineoplastic Agents (adverse effects)
  • Bone Neoplasms (complications, therapy)
  • Cardiomyopathies (epidemiology, etiology)
  • Disease-Free Survival
  • Doxorubicin (adverse effects)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Musculoskeletal Diseases (epidemiology, etiology)
  • Netherlands (epidemiology)
  • Osteosarcoma (complications, therapy)
  • Prevalence
  • Sarcoma, Ewing (complications, therapy)
  • Survivors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: